Articles published by BeiGene, Ltd.
![](https://mms.businesswire.com/media/20230919543475/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
September 19, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20230919525395/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
September 19, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20230802378536/en/1856833/22/BGNE_23_018_EarningsInforgraphic_V8.jpg)
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
August 02, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20230526005277/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
![](https://mms.businesswire.com/media/20230504005408/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
![](https://mms.businesswire.com/media/20230417005339/en/1764923/22/SpringWorks_Logo.jpg)
![](https://mms.businesswire.com/media/20230227005334/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results
February 27, 2023
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20221108006299/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
BeiGene Reports Third Quarter 2022 Financial Results
November 09, 2022
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20220804005380/en/1199527/5/BGNE_Logo_0821.jpg)
BeiGene Reports Second Quarter 2022 Financial Results
August 04, 2022
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20220516006111/en/1199527/5/BGNE_Logo_0821.jpg)
BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland
May 17, 2022
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20220505005431/en/1199527/5/BGNE_Logo_0821.jpg)
BeiGene Reports First Quarter 2022 Financial Results
May 05, 2022
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20220426005559/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20220411005299/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20220224006152/en/1199527/5/BGNE_Logo_0821.jpg)
BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results
February 25, 2022
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://mms.businesswire.com/media/20220106005333/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20211220005226/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20211214006363/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://mms.businesswire.com/media/20211130005710/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20211123005799/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20211123005577/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20211104006165/en/1199527/5/BGNE_Logo_0821.jpg)
BeiGene Reports Third Quarter 2021 Financial Results
November 04, 2021
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20210920005241/en/1199527/5/BGNE_Logo_0821.jpg)
BeiGene Announces Inclusion in FTSE Russell Indices
September 20, 2021
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20210915005310/en/906368/4/Brukinsa.jpg)
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
September 15, 2021
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20210912005031/en/1199527/5/BGNE_Logo_0821.jpg)
BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma
September 13, 2021
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20210912005021/en/1199527/5/BGNE_Logo_0821.jpg)
BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021
September 12, 2021
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20210901006049/en/902566/5/BeiGene_10_Years.jpg)
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström’s Macroglobulinemia
September 01, 2021
From BeiGene, Ltd.
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20210822005013/en/836052/5/BeiGene_10_Years.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.